RESUMO
As a consequence of obstetric complications, neonatal hypoxia has been discussed as an environmental factor in the pathophysiology of schizophrenia. However, the biological consequences of hypoxia are unclear. The neurodevelopmental hypothesis of schizophrenia suggests that the onset of abnormal brain development and neuropathology occurs perinatally, whereas symptoms of the disease appear in early adulthood. In our animal model of chronic neonatal hypoxia, we have detected behavioral alterations resembling those known from schizophrenia. Disturbances in cell proliferation possibly contribute to the pathophysiology of this disease. In the present study, we used postnatal rats to investigate cell proliferation in several brain areas following neonatal hypoxia. Rats were repeatedly exposed to hypoxia (89 % N(2), 11 % O(2)) from postnatal day (PD) 4-8. We then evaluated cell proliferation on PD 13 and 39, respectively. These investigations were performed in the anterior cingulate cortex (ACC), caudate-putamen (CPU), dentate gyrus, and subventricular zone. Rats exposed to hypoxia exhibited increased cell proliferation in the ACC at PD 13, normalizing at PD 39. In other brain regions, no alterations have been detected. Additionally, hypoxia-treated rats showed decreased CPU volume at PD 13. The results of the present study on the one hand support the assumption of chronic hypoxia influencing transient cell proliferation in the ACC, and on the other hand reveal normalization during ageing.
Assuntos
Proliferação de Células , Giro do Cíngulo/patologia , Hipóxia/patologia , Fatores Etários , Análise de Variância , Animais , Animais Recém-Nascidos , Bromodesoxiuridina/metabolismo , Modelos Animais de Doenças , Giro do Cíngulo/crescimento & desenvolvimento , Masculino , Ratos , Ratos Sprague-DawleyRESUMO
Alzheimer disease is the most common cause of dementia among the elderly, accounting for ~60-70% of all cases of dementia. The neuropathological hallmarks of Alzheimer disease are senile plaques (mainly containing p-amyloid peptide derived from amyloid precursor protein) and neurofibrillary tangles (containing hyperphosphorylated Tau protein), along with neuronal loss. At present there is no effective treatment for Alzheimer disease. Given the prevalence and poor prognosis of the disease, the development of animal models has been a research priority to understand pathogenic mechanisms and to test therapeutic strategies. Most cases of Alzheimer disease occur sporadically in people over 65 years old, and are not genetically inherited. Roughly 5% of patients with Alzheimer disease have familial Alzheimer disease--that is, related to a genetic predisposition, including mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes. The discovery of genes for familial Alzheimer disease has allowed transgenic models to be generated through the overexpression of the amyloid precursor protein and/or presenilins harboring one or several mutations found in familial Alzheimer disease. Although none of these models fully replicates the human disease, they have provided valuable insights into disease mechanisms as well as opportunities to test therapeutic approaches. This review describes the main transgenic mouse models of Alzheimer disease which have been adopted in Alzheimer disease research, and discusses the insights into Alzheimer disease pathogenesis from studies in such models. In summary, the Alzheimer disease mouse models have been the key to understanding the roles of soluble b-amyloid oligomers in disease pathogenesis, as well as of the relationship between p-amyloid and Tau pathologies.
Assuntos
Doença de Alzheimer/genética , Precursor de Proteína beta-Amiloide/genética , Modelos Animais de Doenças , Mutação/genética , Precursor de Proteína beta-Amiloide/metabolismo , Animais , Humanos , Camundongos , Camundongos TransgênicosRESUMO
Fluidity is an important neuronal membrane property and it is influenced by the concentration of polyunsaturated fatty acids (PUFAs) in membrane phospholipids. Phospholipase A(2) (PLA(2)) is a key enzyme in membrane phospholipid metabolism, generating free PUFAs. In Alzheimer disease (AD), reduced PLA(2) activity, specifically of calcium-dependent cytosolic PLA(2) (cPLA(2)) and calcium-independent intracellular PLA(2) (iPLA(2)), and phospholipid metabolism was reported in the frontal cortex and hippocampus. This study investigated the effects of in vivo infusion of the dual cPLA(2) and iPLA(2) inhibitor MAFP into rat brain on PLA(2) activity and membrane fluidity parameters in the postmortem frontal cortex and dorsal hippocampus. PLA(2) activity was measured by radioenzymatic assay and membrane fluidity was determined by fluorescence anisotropy technique using three different probes: DPH, TMA-DPH, and pyrene. MAFP significantly inhibited PLA(2) activity, reduced the flexibility of fatty acyl chains (indicated by increased DPH anisotropy), increased the fluidity in the lipid-water interface (indicated by decreased TMA-DPH anisotropy), and increased the lipid lateral diffusion in the hydrocarbon core (represented by pyrene excimer formation) of membranes in both brain areas. The findings suggest that reduced cPLA(2) and iPLA(2) activities in AD brain might contribute to the cognitive impairment, in part, through alterations in membrane fluidity parameters.
Assuntos
Encéfalo/fisiologia , Fluidez de Membrana/fisiologia , Fosfolipases A2/metabolismo , Doença de Alzheimer/metabolismo , Animais , Ácidos Araquidônicos/farmacologia , Encéfalo/metabolismo , Encéfalo/fisiopatologia , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/farmacologia , Humanos , Masculino , Fluidez de Membrana/efeitos dos fármacos , Organofosfonatos/farmacologia , Inibidores de Fosfolipase A2 , Fosfolipases A2/sangue , Ratos , Ratos WistarRESUMO
The microtubule-associated protein Tau promotes the assembly and stability of microtubules in neuronal cells. Six Tau isoforms are expressed in adult human brain. All six isoforms become abnormally hyperphosphorylated and form neurofibrillary tangles in Alzheimer disease (AD) brains. In AD, reduced activity of phospholipase A(2) (PLA(2)), specifically of calcium-dependent cytosolic PLA(2) (cPLA(2)) and calcium-independent intracellular PLA(2) (iPLA(2)), was reported in the cerebral cortex and hippocampus, which positively correlated with the density of neurofibrillary tangles. We previously demonstrated that treatment of cultured neurons with a dual cPLA(2) and iPLA(2) inhibitor, methyl arachidonyl fluorophosphonate (MAFP), decreased total Tau levels and increased Tau phosphorylation at Ser(214) site. The aim of this study was to conduct a preliminary investigation into the effects of in vivo infusion of MAFP into rat brain on PLA(2) activity and total Tau levels in the postmortem frontal cortex and dorsal hippocampus. PLA(2) activity was measured by radioenzymatic assay and Tau levels were determined by Western blotting using the anti-Tau 6 isoforms antibody. MAFP significantly inhibited PLA(2) activity in the frontal cortex and hippocampus. The reactivity to the antibody revealed three Tau protein bands with apparent molecular weight of close to 40, 43 and 46 kDa in both brain areas. MAFP decreased the 46 kDa band intensity in the frontal cortex, and the 43 and 46 kDa band intensities in the hippocampus. The results indicate that in vivo PLA(2) inhibition in rat brain decreases the levels of total (nonphosphorylated plus phosphorylated) Tau protein and corroborate our previous in vitro findings.
Assuntos
Lobo Frontal/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Inibidores de Fosfolipase A2 , Proteínas tau/antagonistas & inibidores , Proteínas tau/metabolismo , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/enzimologia , Doença de Alzheimer/metabolismo , Animais , Ácidos Araquidônicos/administração & dosagem , Avaliação Pré-Clínica de Medicamentos/métodos , Lobo Frontal/enzimologia , Lobo Frontal/metabolismo , Hipocampo/metabolismo , Humanos , Masculino , Neurônios/efeitos dos fármacos , Neurônios/enzimologia , Neurônios/metabolismo , Organofosfonatos/administração & dosagem , Fosfolipases A2/metabolismo , Ratos , Ratos WistarRESUMO
Alzheimer disease is the most common cause of dementia among the elderly, accounting for ~60-70 percent of all cases of dementia. The neuropathological hallmarks of Alzheimer disease are senile plaques (mainly containing p-amyloid peptide derived from amyloid precursor protein) and neurofibrillary tangles (containing hyperphosphorylated Tau protein), along with neuronal loss. At present there is no effective treatment for Alzheimer disease. Given the prevalence and poor prognosis of the disease, the development of animal models has been a research priority to understand pathogenic mechanisms and to test therapeutic strategies. Most cases of Alzheimer disease occur sporadically in people over 65 years old, and are not genetically inherited. Roughly 5 percent of patients with Alzheimer disease have familial Alzheimer disease-that is, related to a genetic predisposition, including mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes. The discovery of genes for familial Alzheimer disease has allowed transgenic models to be generated through the overexpression of the amyloid precursor protein and/or presenilins harboring one or several mutations found in familial Alzheimer disease. Although none of these models fully replicates the human disease, they have provided valuable insights into disease mechanisms as well as opportunities to test therapeutic approaches. This review describes the main transgenic mouse models of Alzheimer disease which have been adopted in Alzheimer disease research, and discusses the insights into Alzheimer disease pathogenesis from studies in such models. In summary, the Alzheimer disease mouse models have been the key to understanding the roles of soluble b-amyloid oligomers in disease pathogenesis, as well as of the relationship between p-amyloid and Tau pathologies.
Assuntos
Animais , Humanos , Camundongos , Doença de Alzheimer/genética , Precursor de Proteína beta-Amiloide/genética , Modelos Animais de Doenças , Mutação/genética , Precursor de Proteína beta-Amiloide/metabolismo , Camundongos TransgênicosRESUMO
The involvement of phospholipase A(2) (PLA(2)) in Alzheimer disease (AD) was first investigated nearly 15 years ago. Over the years, several PLA(2) isoforms have been detected in brain tissue: calcium-dependent secreted PLA(2) or sPLA(2) (IIA, IIC, IIE, V, X, and XII), calcium-dependent cytosolic PLA(2) or cPLA(2) (IVA, IVB, and IVC), and calcium-independent PLA(2) or iPLA(2) (VIA and VIB). Additionally, numerous in vivo and in vitro studies have suggested the role of different brain PLA(2) in both physiological and pathological events. This review aimed to summarize the findings in the literature relating the different brain PLA(2) isoforms with alterations found in AD, such as neuronal cell death and impaired neurogenesis process. The review showed that sPLA(2)-IIA, sPLA(2)-V and cPLA(2)-IVA are involved in neuronal death, whereas sPLA(2)-III and sPLA(2)-X are related to the process of neurogenesis, and that the cPLA(2) and iPLA(2) groups can be involved in both neuronal death and neurogenesis. In AD, there are reports of reduced activity of the cPLA(2) and iPLA(2) groups and increased expression of sPLA(2)-IIA and cPLA(2)-IVA. The findings suggest that the inhibition of cPLA(2) and iPLA(2) isoforms (yet to be determined) might contribute to impaired neurogenesis, whereas stimulation of sPLA(2)-IIA and cPLA(2)-IVA might contribute to neurodegeneration in AD.
Assuntos
Doença de Alzheimer/enzimologia , Doença de Alzheimer/patologia , Neurogênese/fisiologia , Neurônios/enzimologia , Neurônios/patologia , Fosfolipases A2/fisiologia , Animais , Morte Celular/fisiologia , Humanos , Neurônios/citologia , Inibidores de Fosfolipase A2RESUMO
BACKGROUND: Arachidonic acid is released from cellular membranes by the action of phospholipase A(2) (PLA(2)) and is implicated in microtubule-associated protein Tau phosphorylation. Tau hyperphosphorylation affects its ability to stabilize microtubules. OBJECTIVE: To determine the effect of PLA(2) inhibition on the phosphorylation state of Tau phosphoepitopes in primary cultures of hippocampal neurons. METHODS: 4 DIC neurons were incubated at different concentrations of methyl-arachidonylfluorophosphonate (MAFP), an irreversible inhibitor of cPLA(2) and iPLA(2). Changes on Tau phosphorylation were determined by Western blotting with a panel of anti-Tau antibodies (C-terminal, Ser199/202, Ser202/205, Ser396 and Ser214). RESULTS: The Ser214 site was hyperphosphorylated upon MAFP treatment. Significant differences were observed with 10 microM (p=0.01), 50 microM (p=0.01) and 100 microM (p=0.05) of MAFP. Less-intense changes were found in other phosphoepitopes. CONCLUSION: The present findings indicate that the phosphorylation of Ser214 is regulated by c- and/or iPLA(2), whereas other phosphoepitopes primarily regulated by GKS3b were not affected.
Assuntos
Hipocampo/embriologia , Neurônios/metabolismo , Inibidores de Fosfolipase A2 , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Serina/metabolismo , Proteínas tau/metabolismo , Animais , Anticorpos Fosfo-Específicos , Ácidos Araquidônicos/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/farmacologia , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Neurônios/efeitos dos fármacos , Organofosfonatos/farmacologia , Fosfolipases A2 Independentes de Cálcio/antagonistas & inibidores , Fosforilação/efeitos dos fármacos , Ratos , Ratos WistarRESUMO
CONTEXTO: Com a descoberta de que a neurogênese constitutiva persiste no cérebro adulto, surgiu a hipótese na literatura de que a doença de Alzheimer (DA) poderia ser superada, ou pelo menos melhorada, visto que a geração de novos neurônios poderia ajudar a compensar a perda de neurônios na doença. OBJETIVOS: Neste trabalho, foi revisada a literatura sobre a neurogênese endógena no cérebro de sujeitos com DA e modelos animais de DA, os efeitos de atividade cognitiva sobre a neurogênese, e a relação entre a enzima fosfolipase A2 (PLA2) e a neurogênese. MÉTODOS: A base de dados MedLine foi pesquisada utilizando as palavras-chave doença de Alzheimer, atividade cognitiva, fosfolipase A2, neurogênese e neuritogênese. RESULTADOS: A revisão da literatura evidenciou neuroproliferação aumentada no cérebro com DA, no entanto, os novos neurônios falham em se diferenciar em neurônios maduros. Uma estratégia não farmacológica, ambiente enriquecido, aumenta a neurogênese (incluindo amadurecimento neuronal) em animais experimentais. Relação entre PLA2 e neurogênese tem sido demonstrada em modelos experimentais in vitro e in vivo. CONCLUSÃO: Os dados indicam que o enriquecimento ambiental (com estimulações cognitiva e física) poderia ser uma estratégia apropriada para promover a neurogênese endógena na DA e sugerem a participação da PLA2 na neurogênese promovida por estimulação cognitiva.
BACKGROUND: With the discovery that constitutive neurogenesis persists in the adult brain, has emerged the hypothesis in the literature that Alzheimer disease (AD) could be overcome, or at least ameliorated, since the generation of new neurons might help to compensate for the loss of neurons in the disease. OBJECTIVES: In this work the literature on endogenous neurogenesis in the brain of subjects with AD and animal models of AD, the effects of cognitive activity on neurogenesis, and the relationship between the enzyme phospholipase A2 (PLA2) and neurogenesis was reviewed. METHODS: MedLine database was searched using the keywords Alzheimer disease, cognitive activity, phospholipase A2, neurogenesis, and neuritogenesis. RESULTS: The literature review evidenced increased neuroproliferation in AD brain, however, the new neurons fail to differentiate into mature neurons. A non-pharmacological strategy, enriched environment, increases neurogenesis (including neuronal maturation) in experimental animals. Relationship between PLA2 and neurogenesis has been demonstrated in in vitro and in vivo experimental models. DISCUSSION: The data indicate that environmental enrichment (with cognitive and physical stimulations) might be a suitable strategy to promote endogenous neurogenesis in AD, and suggest the participation of PLA2 in the neurogenesis promoted by cognitive stimulation.
Assuntos
Atividade Nervosa Superior , Cognição , Doença de Alzheimer/diagnóstico , Fosfolipases A/análiseRESUMO
Adult neurogenesis occurs in the subgranular zone (SGZ) and subventricular zone (SVZ). New SGZ neurons migrate into the granule cell layer of the dentate gyrus (DG). New SVZ neurons seem to enter the association neocortex and entorhinal cortex besides the olfactory bulb. Alzheimer disease (AD) is characterized by neuron loss in the hippocampus (DG and CA1 field), entorhinal cortex, and association neocortex, which underlies the learning and memory deficits. We hypothesized that, if the AD brain can support neurogenesis, strategies to stimulate the neurogenesis process could have therapeutic value in AD. We reviewed the literature on: (a) the functional significance of adult-born neurons; (b) the occurrence of endogenous neurogenesis in AD; and (c) strategies to stimulate the adult neurogenesis process. We found that: (a) new neurons in the adult DG contribute to memory function; (b) new neurons are generated in the SGZ and SVZ of AD brains, but they fail to differentiate into mature neurons in the target regions; and (c) numerous strategies (Lithium, Glatiramer Acetate, nerve growth factor, environmental enrichment) can enhance adult neurogenesis and promote maturation of newly generated neurons. Such strategies might help to compensate for the loss of neurons and improve the memory function in AD.
Assuntos
Células-Tronco Adultas/fisiologia , Doença de Alzheimer/terapia , Encéfalo/citologia , Neurogênese/fisiologia , Neurônios/fisiologia , Células-Tronco Adultas/efeitos dos fármacos , Doença de Alzheimer/patologia , Doença de Alzheimer/fisiopatologia , Animais , Antipsicóticos/farmacologia , Antipsicóticos/uso terapêutico , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/fisiologia , Humanos , Neurogênese/efeitos dos fármacos , Neurônios/efeitos dos fármacosRESUMO
RATIONALE: Alzheimer disease (AD) is the leading cause of dementia in the elderly and has no known cure. Evidence suggests that reduced activity of specific subtypes of intracellular phospholipases A2 (cPLA2 and iPLA2) is an early event in AD and may contribute to memory impairment and neuropathology in the disease. OBJECTIVE: The objective of this study was to review the literature focusing on the therapeutic role of PLA2 stimulation by cognitive training and positive modulators, or of supplementation with arachidonic acid (PLA2 product) in facilitating memory function and synaptic transmission and plasticity in either research animals or human subjects. METHODS: MEDLINE database was searched (no date restrictions) for published articles using the keywords Alzheimer disease (mild, moderate, severe), mild cognitive impairment, healthy elderly, rats, mice, phospholipase A(2), phospholipid metabolism, phosphatidylcholine, arachidonic acid, cognitive training, learning, memory, long-term potentiation, protein kinases, dietary lipid compounds, cell proliferation, neurogenesis, and neuritogenesis. Reference lists of the identified articles were checked to select additional studies of interest. RESULTS: Overall, the data suggest that PLA2 activation is induced in the healthy brain during learning and memory. Furthermore, learning seems to regulate endogenous neurogenesis, which has been observed in AD brains. Finally, PLA2 appears to be implicated in homeostatic processes related to neurite outgrowth and differentiation in both neurodevelopmental processes and response to neuronal injury. CONCLUSION: The use of positive modulators of PLA2 (especially of cPLA2 and iPLA2) or supplementation with dietary lipid compounds (e.g., arachidonic acid) in combination with cognitive training could be a valuable therapeutic strategy for cognitive enhancement in early-stage AD.